首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1845878

2024-2031 年血管成形術用氣球和支架市場：按產品、適應症、最終用戶和地區分類

Angioplasty Balloons And Stents Market By Product (Stents, Balloons), Indication (Coronary Artery Diseases, Peripheral Artery Diseases), End-User (Hospitals, Ambulatory Surgical Centers, Cath Labs), And Region For 2024-2031

出版日期: 2025年09月21日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血管成形術用氣球和支架市場評估 - 2024-2031

微創手術的進步和心血管疾病發病率的上升正在推動血管成形術球囊和支架市場的發展。根據 Verified Market Research 分析師預測，2024 年血管成形術用氣球和支架市場規模約 67.7 億美元，預測期內將達到 97.5 億美元。

經經皮冠狀動脈介入治療的增加、技術進步提高了產品功效以及老齡化人口更容易患心血管疾病是推動血管成形術用氣球和支架市場強勁成長的因素，預計從 2024 年到 2031 年，該市場的複合年成長率將達到 4.67%。

血管成形術用氣球和支架市場定義/概述

血管成形術用氣球和支架是用於治療血流受限或阻塞的醫療設備，主要用於治療心臟冠狀動脈血流受限或阻塞。血管成形術用氣球是一種可充氣裝置，當插入受限的動脈時，球囊會擴張以拓寬導管並恢復血流。而支架是一種小型網狀管，通常由金屬或聚合物製成，在球囊血管成形術過程中插入動脈。支架起到支撐作用，保持動脈暢通，防止再次狹窄。

此外，這些裝置通常用於治療冠狀動脈疾病 (CAD)。冠狀動脈疾病是指動脈中積聚的脂肪沉積物（稱為斑塊）導致心肌血流減少所引發的疾病。透過恢復正常的心臟血流，血管成形術用氣球和支架可以緩解冠狀動脈疾病的症狀，例如胸痛（心絞痛），並降低心臟病發作的風險。它們也用於治療周邊動脈疾病( PAD)。周邊動脈疾病是指腿部、手部、足部和身體其他部位的動脈變窄或阻塞，導致腿部不適和麻木等症狀。

推動血管成形術用氣球和支架市場成長的關鍵因素是什麼？

全球心血管疾病盛行率的上升是血管成形術用氣球和支架市場的主要驅動力。隨著越來越多的人被診斷出患有冠狀動脈疾病等心臟相關疾病，對血管成形術等微創手術的需求也日益成長。這項技術使用球囊和支架來打通受限或阻塞的動脈，增加流向心臟的血流量。

血管成形術球囊和支架的技術已取得顯著進步，使其更加安全、有效和可靠。例如，藥物釋放型支架 (DES) 的發明代表了一項重大進步，它能夠緩慢釋放藥物，防止動脈再次阻塞。此外，生物可吸收血管支架的引入以及球囊導管技術的進步改善了患者的治療效果，並刺激了市場擴張。

此外，全球人口結構正在經歷老化。由於心血管系統的自然老化、長期風險因素的累積以及高血壓、糖尿病和肥胖等併發症的存在，老年人更容易患上心血管疾病。這些人口趨勢導致需要血管成形術治療的患者數量增加，從而推動了對球囊和支架的需求。

影響市場成長的挑戰有哪些？

儘管技術不斷發展，血管成形術和支架植入置入術仍充滿風險和潛在併發症，例如血栓、動脈狹窄（血管再阻塞）、導管插入部位出血，以及在極少數情況下發生的動脈破裂。這些風險使患者不願接受這些手術，並可能使製造商和醫療保健提供者面臨法律和財務後果，從而限制市場擴張。

此外，心血管疾病管理的替代治療方法和技術也為血管成形術用氣球和支架市場帶來了壓力。冠狀動脈繞道手術手術 (CABG) 等外科手術為一些患有嚴重冠狀動脈疾病的患者提供了更持久的解決方案。此外，針對動脈阻塞根本原因的新藥和非侵入性治療方法的開發與血管成形術和支架置入術構成了競爭。這些治療方案因患者病情和醫療專業人員的建議而異，這阻礙了血管成形術用氣球和支架市場的擴張。

Advancements in minimally invasive procedures, as well as an increasing frequency of cardiovascular disorders, are propelling the Angioplasty Balloons And Stents Market. According to the analyst from Verified Market Research, the Angioplasty Balloons And Stents Market is estimated to reach a valuation of USD 9.75 Billion over the forecast subjugating around USD 6.77 Billion valued in 2024.

Increasing use of percutaneous coronary intervention procedures, advancements in technology that improve product efficacy, and an aging population that is more vulnerable to cardiovascular diseases are all contributing factors to the Angioplasty Balloons And Stents Market's strong growth. This enables the market to grow at a CAGR of 4.67% from 2024 to 2031.

Angioplasty Balloons And Stents Market: Definition/ Overview

Angioplasty Balloons and stents are medical devices that treat restricted or obstructed blood channels, primarily in the coronary arteries of the heart. Angioplasty balloons are inflatable devices that, once put into a restricted artery, expand to enlarge the conduit and restore blood flow. Stents, on the other hand, are small mesh tubes usually made of metal or polymer that are inserted into the artery during balloon angioplasty. They operate as scaffolding, keeping the artery open and preventing it from narrowing again.

Furthermore, these devices are generally used to treat coronary artery disease (CAD), which develops when fatty deposits known as plaque accumulate inside the arteries, reducing blood flow to the heart muscle. Angioplasty balloons and stents assist relieve CAD symptoms, such as chest pain (angina), and lower the risk of a heart attack by restoring appropriate blood flow to the heart. They are also used to treat peripheral artery disease (PAD), which occurs when arteries in the legs, limbs, or other regions of the body narrow or get clogged, causing symptoms such as leg discomfort or numbness.

What are the Key Factors Driving the Growth of the Angioplasty Balloons And Stents Market?

The rising global incidence of cardiovascular illnesses is a major driver of the Angioplasty Balloons And Stents Market. The need for minimally invasive surgeries like angioplasty is rising as more people receive diagnoses for heart-related disorders, such as coronary artery disease. This technique employs balloons and stents to widen restricted or obstructed arteries, increasing blood flow to the heart.

The technology behind angioplasty balloons and stents has advanced significantly, making them safer, more effective, and more reliable. For example, the invention of drug-eluting stents (DES) that slowly release medication to keep the artery from becoming blocked again has resulted in tremendous progress. Also, the introduction of bioresorbable vascular scaffolds and advances in balloon catheter technology help to improve patient outcomes and fuel market expansion.

Furthermore, the world is experiencing a demographic shift toward an elderly population. Older people are more likely to acquire cardiovascular disorders as a result of natural aging of the cardiovascular system, the accumulation of risk factors over time, and the existence of comorbid conditions such as hypertension, diabetes, and obesity. This demographic trend increases the number of patients who require angioplasty treatments, which drives up demand for balloons and stents.

What are the Challenges Influencing the Growth of the Market?

Despite technological developments, angioplasty and stent implantation operations continue to pose risks and potential complications, including blood clots, arterial narrowing (restenosis), bleeding at the catheter insertion site, and, in rare circumstances, artery rupture. These hazards prevent patients from undergoing these operations and might result in legal and financial consequences for manufacturers and healthcare providers, thereby limiting market expansion.

Furthermore, alternative treatment procedures and technology for cardiovascular disease management are putting pressure on the market for angioplasty balloons and stents. Surgical procedures, such as coronary artery bypass grafting (CABG), provide a more permanent solution for some patients with severe coronary artery disease. Also, the development of new medications and non-invasive treatments that address the underlying causes of artery blockages competes with angioplasty and stenting operations. The choice for these alternatives, which vary based on the patient's condition and the recommendation of their healthcare professional, poses a barrier to the market expansion of angioplasty balloons and stents.

Category-Wise Acumens

How is the Demand for Stents Increasing in the Market?

According to VMR analysis, the stents segment is estimated to hold the largest market share during the forecast period. Stents, particularly drug-eluting stents (DES), have evolved dramatically over time. These stents not only keep the artery open, but they also release medication over time to keep it from being blocked again (restenosis). This dual function considerably improves patient outcomes and reduces the need for additional operations. Continuous innovation in stent technology, such as the creation of bioresorbable stents and advances in the materials and coatings utilized, improves their efficacy and safety profile, making them the preferred treatment option for coronary artery disease.

Stents are used in a wider spectrum of cardiovascular diseases than angioplasty balloons. While balloons are primarily used to widen the artery, stents give structural support to keep it from narrowing further. This means that stents can be used not only for coronary artery disease but also for peripheral artery disease and other vascular interventions, boosting their utility and adoption in a broader range of cardiovascular treatments.

Furthermore, many healthcare systems have more favorable payment policies for stent implantation treatments due to their demonstrated efficacy and long-term advantages in controlling coronary artery disease. Healthcare providers and patients frequently prefer treatments that are covered by insurance or have higher reimbursement rates, contributing to the stents segment's market dominance. Also, as healthcare systems and insurance companies understand the cost-effectiveness of stent implantations in minimizing the need for future cardiovascular treatments, the use of stents is increasing.

How Does Coronary Artery Disease (CAD) Support the Growing Demand in the Market?

The coronary artery diseases (CAD) segment is estimated to exhibit the highest growth within the Angioplasty Balloons And Stents Market during the forecast period. CAD is a primary cause of morbidity and mortality worldwide, affecting a large proportion of the adult population. Sedentary lifestyles, bad diets, smoking, hypertension, diabetes, and high cholesterol all contribute to the condition's prevalence. The high global incidence of CAD creates a significant demand for angioplasty procedures and the use of balloons and stents as major therapies to restore blood flow in constricted or blocked coronary arteries.

There has been a huge increase in awareness of heart disease and its symptoms, which has resulted in higher CAD diagnostic rates. Advances in diagnostic tools, such as coronary angiograms, CT scans, and MRIs, have made it simpler to detect CAD early on. Early detection increases the possibility of patients receiving angioplasty operations, driving up demand for coronary stents and balloons.

Furthermore, the segment has seen tremendous technological breakthroughs, such as the introduction of drug-eluting stents, bioresorbable stents, and cutting-edge balloon catheter technologies. These developments have increased the safety, efficacy, and patient outcomes of angioplasty operations for CAD. Modern coronary stents and balloons are the recommended treatment for CAD due to their improved performance and lower complication rates, which contributes to their leading market position.

Country/Region-wise Acumens

How is the High Prevalence of Cardiovascular Diseases Driving the Market in North America?

According to VMR analyst, North America is estimated to dominate the Angioplasty Balloons And Stents Market during the forecast period. Sedentary lifestyles, obesity, diabetes, and smoking all contribute to the region's high prevalence of cardiovascular disease. This large patient population needs the use of efficient treatment options, such as angioplasty with balloons and stents, to manage and treat coronary and peripheral artery disorders, hence driving the market.

North America, particularly the United States, has one of the world's most advanced healthcare infrastructures. This includes extensive access to advanced medical facilities, highly skilled healthcare professionals, and cutting-edge medical technology. A strong healthcare system promotes early detection, treatment, and management of cardiovascular disorders, such as coronary and peripheral artery disease, increasing demand for angioplasty balloons and stents.

Furthermore, North America, especially the United States, offers advantageous payment regulations for cardiovascular operations, making treatments such as angioplasty more affordable to a wider range of the population. When combined with the region's good economic conditions, these factors contribute to increased healthcare spending, particularly modern medical equipment for cardiovascular procedures. Furthermore, the presence of major medical device makers in the region, together with significant R&D investments, drives market expansion.

What are the Main Drivers of the Angioplasty Balloons And Stents Market in Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia Pacific region has the world's largest population, including a sizable senior population that is more susceptible to cardiovascular diseases (CVDs). Japan has one of the largest numbers of aged people in the world, while China and India are seeing substantial rises in their aging populations. This generational shift raises the incidence of coronary and peripheral arterial disorders, driving up demand for angioplasty operations and associated devices.

Many Asia Pacific countries are making significant changes to their healthcare systems, including expanding healthcare facilities and services to rural and underserved communities. Increased healthcare spending, combined with government attempts to improve healthcare infrastructure and accessibility, has made modern medical treatments, such as angioplasty with balloons and stents, more accessible to a wider range of patients.

Furthermore, the region has undergone tremendous economic expansion in recent decades, resulting in increased healthcare spending by both governments and people. Growing health awareness, higher disposable incomes, and the inclusion of modern medical procedures in insurance coverages have made Asian Pacific communities more proactive in seeking cardiovascular disease therapy. Also, the existence of growing economies such as China and India helps to build a middle class that can afford more advanced healthcare alternatives.

Competitive Landscape

The competitive landscape of the Angioplasty Balloons And Stents Market is characterized by fierce competition caused by a variety of factors. Also, market participants are focusing on extending their geographical presence to enter emerging countries and capitalize on the growing demand for minimally invasive cardiovascular procedures.

Some of the prominent players operating in the Angioplasty Balloons And Stents Market include:

Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cook Medical, Biosensors International Group, MicroPort Scientific Corporation, Terumo Corporation, Stentys SA, Biotronik, Becton, Dickinson and Company, Cordis Corp, AngioDynamics, Braun Melsungen AG, Philips, Oscor Inc., Royal DSM N.V., Spectranetics Corp.

Latest Developments

In April 2024, Abbott reported positive long-term data from the ABSORB absorbable scaffold platform at EuroPCR 2024.

In March 2024, Medtronic announced the U.S. FDA approval of the Resolute Onyx DES with EverFlex Technology for the treatment of coronary artery disease.

In February 2024, Boston Scientific announced the global launch of EXILIFE DES*, a next-generation drug-eluting stent for coronary artery disease.

1 INTRODUCTION OF GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET, BY PRODUCT

5.1 Overview
5.2 Stents
5.3 Balloons

6 GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET, BY END-USER

6.1 Overview
6.2 Hospitals
6.3 Ambulatory Surgical Centers
6.4 Cath Labs
6.5 Others

7 GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET, BY INDICATION

7.1 Overview
7.2 Coronary Artery Diseases
7.3 Peripheral Artery Diseases

8 GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East

9 GLOBAL ANGIOPLASTY BALLOONS AND STENTS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Medtronic plc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Abbott Laboratories
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Boston Scientific Corporation
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Cook Medical
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Biosensors International Group
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 MicroPort Scientific Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Terumo Corporation
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Stentys SA
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Biotronik
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Becton
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments